Physician profile
Ajay Labroo
NPI 1831199371
$9,566.41
in general payments reported to CMS, 2019-2025
28 companies · $225 in 2025
The $225 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,019 · 2020: $709 · 2021: $465 · 2022: $432 · 2023: $1,048 · 2024: $668 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,748 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,747.65 |
| Education | $193.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $5,679.80 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $702.00 | 2019-2024 | Uptravi, Opsumit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $449.94 | 2019-2025 | Lifevest |
| Abbott Laboratories | $327.24 | 2022-2023 | Jot Dx |
| Boston Scientific Corporation | $321.94 | 2019-2023 | |
| Amarin Pharma, INC. | $259.20 | 2019-2021 | |
| Shockwave Medical, INC | $238.42 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $222.11 | 2019-2024 | Repatha |
| Merck Sharp & Dohme LLC | $175.41 | 2022-2024 | Verquvo, Winrevair |
| Philips North America LLC | $165.17 | 2019-2024 | (P84) Igt Devices Systems |
| Kowa Pharmaceuticals America, INC. | $153.92 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $147.07 | 2019-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $127.15 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $108.23 | 2019-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $75.23 | 2022-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opsens INC. | $70.77 | 2019-2020 | |
| Medtronic, INC. | $59.46 | 2021-2023 | Micra |
| Pfizer INC. | $53.74 | 2023 | |
| Aerin Medical INC. | $43.13 | 2019 | |
| Daiichi Sankyo INC. | $38.73 | 2023 | Injectafer |
| United Therapeutics Corporation | $30.68 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $25.97 | 2023 | |
| Impulse Dynamics (USA) INC. | $22.06 | 2023 | Optimizer |
| Terumo Medical Corporation | $19.92 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $19.44 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $18.79 | 2024 | Arcalyst |
| Gilead Sciences, INC. | $10.89 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Labroo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.